Case Reports in Oncology最新文献

{"title":"Timing of Renal Transplant in Survivor Children with Relapse of Wilms Tumor: A Case Series Study.","authors":"Teresa Battaglia, Pietro Casartelli, Monica Muraca, Stefania Sorrentino, Sabrina Zanardi, Fiammetta Sertorio, Gaetano Valerio Vellone, Alberto Magnasco, Alberto Garaventa, Loredana Amoroso","doi":"10.1159/000543176","DOIUrl":"10.1159/000543176","url":null,"abstract":"<p><strong>Introduction: </strong>Children with Wilms tumor can rarely experience late relapse of disease. Sometimes bilateral nephrectomy is necessary; as a consequence, the patient needs hemodialysis while waiting for renal transplantation. The waiting time to transplantation after cancer has always been a debated issue.</p><p><strong>Case presentation: </strong>We present 2 cases of late relapse of Wilms tumor who underwent bilateral nephrectomy. Patient 1 was put in the attending list for renal transplant after 5 years to stop treatment, attending the conventional time; however, she died before transplant because of complications in SARS-COVID-19 infection. Patient 2 underwent a renal transplant sooner compared to the conventional time, improving her quality of life and alive.</p><p><strong>Conclusion: </strong>If bilateral nephrectomy is necessary in oncological patients, the timing of renal transplant should be discussed by multidisciplinary team. In our cases, the different time to renal transplantation was associated with different outcomes. Clinicians should have common lines about the time of renal transplantation in pediatric oncology; however, a personalized planning could be suggested after discussion among specialists, evaluating case to case. The presented field needs more knowledge and further larger case series are necessary to evaluate outcome related to the timing of renal transplant; in this view, collaboration between oncology centers is strongly required.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"449-455"},"PeriodicalIF":0.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143778910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in Osteoblastic Bone Metastasis Detected Incidentally by Cone-Beam Computed Tomography: A Case Report.","authors":"Uchina Hiya, Masashi Endo, Kohei Okada, Satoru Takahashi, Kazunari Ogawa, Machi Nakagawa, Michiko Nakamura, Chiaki Shibayama, Yukiko Fukuda, Keiko Akahane, Masahiro Kawahara, Harushi Mori, Katsuyuki Shirai","doi":"10.1159/000545252","DOIUrl":"https://doi.org/10.1159/000545252","url":null,"abstract":"<p><strong>Introduction: </strong>Although cone-beam computed tomography (CBCT) is essential for tumor positioning in image-guided radiotherapy, its diagnostic application is limited by low image quality. This report highlights a case where CBCT unexpectedly detected osteoblastic bone metastasis during radiotherapy for prostate cancer.</p><p><strong>Case presentation: </strong>A 65-year-old man with recurrent prostate cancer underwent postoperative intensity-modulated radiotherapy of 66 Gy in 33 fractions. Two months after treatment, an increase in prostate-specific antigen (PSA) levels led us to perform imaging that revealed a new osteoblastic metastasis in the left acetabulum. A retrospective review of the CBCT scans obtained during radiotherapy showed progressive osteoblastic changes that were not visible on pre-treatment imaging.</p><p><strong>Conclusion: </strong>The progressive changes in osteoblastic bone metastases on CBCT highlight its potential usefulness in daily monitoring and evaluation during radiotherapy.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"493-499"},"PeriodicalIF":0.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12028975/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Response to Enfortumab Vedotin and Pembrolizumab in a Patient with Vaginal Squamous Cell Carcinoma: A Case Report.","authors":"Michael Glover, Isabel Beshar, Austin McHenry, Cornelia Ding, Oliver Dorigo, Emily Chan, Sumit A Shah","doi":"10.1159/000545141","DOIUrl":"https://doi.org/10.1159/000545141","url":null,"abstract":"<p><strong>Introduction: </strong>Vaginal cancer is a rare yet aggressive cancer, with unmet need for novel therapeutics.</p><p><strong>Case presentation: </strong>In this case report, we present a patient with advanced stage, HPV-positive vaginal cancer who demonstrated clinical, radiological, and molecular response to combination treatment of antibody-drug conjugate enfortumab vedotin (EV) with pembrolizumab.</p><p><strong>Conclusion: </strong>This is the first reported response to this combination therapy in vaginal cancer in the literature. The patient had positive Nectin-4 staining on evaluation, raising the possibility for future clinical application of EV in vaginal squamous cell cancer.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"473-479"},"PeriodicalIF":0.7,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11999660/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncolytic Virotherapy for Relapsed, IDH-Mutant, Grade 3 Astrocytoma: A New Promising Approach - A Case Report.","authors":"Benjamin Gesundheit, Jayadeepa Srinivas Raju, Chaim Y Brauns, Christine Weisslein, Harald Schmoll, Ronald Ellis, Yehudit Posen, Andreas Schmitz, Hüseyin Sahinbas","doi":"10.1159/000545004","DOIUrl":"10.1159/000545004","url":null,"abstract":"<p><strong>Introduction: </strong>IDH-mutant astrocytomas are high-grade gliomas with a poor prognosis. Transformation to glioblastoma multiforme is common, which further shortens overall survival and frequently renders the tumor inoperable. Oncolytic viruses (OVs) have been shown to be safe and effective agents for the treatment of some malignant brain tumors. Intra-tumoral application may further enhance their therapeutic potential.</p><p><strong>Case presentation: </strong>This report presents a case of a 37-year-old female patient with advanced relapsed grade 3 astrocytoma, with multiple foci, including one along the rim of the left fronto-parietal post-op cavity, who was treated with a one-shot OV regimen via an Ommaya reservoir (IO-OV), with the catheter tip placed intra-tumorally. Adjunct electro-hyperthermia therapy was also provided. No evidence of disease (NED) was achieved after the first cycle of IO-OV and was maintained for 9 months until the non-vaccinated patient contracted COVID-19, after which aggressive and refractory relapse occurred.</p><p><strong>Conclusion: </strong>OV therapy proved to induce significant clinical improvements and radiological NED for this incurable astrocytoma. This promising modality should be evaluated as an adjunct to first-line therapy for inoperable brain tumors.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"462-472"},"PeriodicalIF":0.7,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975348/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Complete Response to Pembrolizumab in Tumor Mutation Burden-High Small Cell Lung Cancer: A Case Report.","authors":"Kiyohide Komuta, Kei Kunimasa, Akito Miyazaki, Shun Futamura, Tsunehiro Tanaka, Takahisa Kawamura, Takako Inoue, Motohiro Tamiya, Kazumi Nishino","doi":"10.1159/000544103","DOIUrl":"10.1159/000544103","url":null,"abstract":"<p><strong>Introduction: </strong>Extensive-stage small-cell lung cancer (ED-SCLC) has a poor prognosis. There are few case reports on the therapeutic effect of pembrolizumab in advanced SCLC with high tumor mutation burden (TMB-high).</p><p><strong>Case presentation: </strong>A 65-year-old woman was diagnosed with ED-SCLC. The initial treatment regimen included carboplatin, etoposide, and durvalumab. Following the administration of durvalumab, etoposide was discontinued due to an anaphylactic reaction immediately after its initiation. The patient was unable to continue the same regimen and was switched to cisplatin and irinotecan therapy. A FoundationOne panel test was submitted at the same time, and TMB-high was detected. After four courses of cisplatin and irinotecan therapy, pembrolizumab was introduced, and a complete response (CR) was maintained for 18 months.</p><p><strong>Conclusion: </strong>We report a rare case of a long-term response to pembrolizumab in ED-SCLC with TMB-high, highlighting the potential for targeted immunotherapy in such cases.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"443-448"},"PeriodicalIF":0.7,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11964409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Post-Endobronchial Ultrasound Polymicrobial Pericarditis and Mediastinitis in Metastatic Renal Cell Carcinoma.","authors":"Viktor Sekowski, Waël Hanna","doi":"10.1159/000544053","DOIUrl":"10.1159/000544053","url":null,"abstract":"<p><strong>Introduction: </strong>Endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) is a frequently used bronchoscopic method for sampling centrally located tumors and accessible mediastinal lymph nodes. It is widely employed for staging and obtaining tissue diagnosis in lung cancer, but it can also be used for other conditions with mediastinal lymph node metastases. Although the reported complication rate for EBUS-TBNA varies, it consistently remains low, including for severe infectious complications such as pericarditis and mediastinitis.</p><p><strong>Case presentation: </strong>We present a unique case of polymicrobial pyogenic pericarditis, mediastinitis, and death in a patient who underwent EBUS-TBNA for the evaluation of solitary mediastinal lymphadenopathy in the background of previously resected renal cell carcinoma. There were no complications during her procedure and her mediastinal lymph node biopsy confirmed metastatic renal cell carcinoma. However, 23 days after her procedure, she presented to the emergency department with sepsis and cardiac tamponade. Pericardial fluid cultures and computed tomography imaging confirmed polymicrobial pyogenic pericarditis and mediastinitis.</p><p><strong>Conclusion: </strong>While complications from EBUS-TBNA are rare, clinicians need to be aware that pericarditis and mediastinitis are possible life-threatening complications in order to facilitate early recognition and interventions.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"456-461"},"PeriodicalIF":0.7,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970877/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric Auricular Angiosarcoma: A Rare Case Report and Review of the Literature.","authors":"Ika Dewi Mayangsari, Ayu Astria Sriyana, Marlinda Adham, Harim Priyono, Aris Rahmanda, Novie Amelia Chozie, Meilania Saraswati, Indrati Suroyo","doi":"10.1159/000543993","DOIUrl":"10.1159/000543993","url":null,"abstract":"<p><strong>Introduction: </strong>Limited evidence exists regarding the clinical characteristics of auricular angiosarcoma in the pediatric population. To our knowledge, this represents the inaugural case report of auricular angiosarcoma in early childhood. This report aims to delineate the unique clinical features and findings associated with pediatric auricular angiosarcoma.</p><p><strong>Case presentation: </strong>We report a 7-year-old girl presented with a 2-year history of an enlarging, intermittently painful purplish-red mass in the left ear canal and undergo surgery with adjuvant chemotherapy.</p><p><strong>Conclusion: </strong>Although a rarity, auricular angiosarcoma can manifest in pediatric patients, necessitating vigilant consideration for diagnosis in this population. The evaluation and management of auricular angiosarcoma in pediatric cases demands heightened caution due to the patients' young age and the high risk of recurrence and metastases following primary treatments.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"429-435"},"PeriodicalIF":0.7,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11952820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reinfusion of Malignant Ascites through an Extracorporeal Peritoneal Venous Shunt to Avoid Complications and Assess the Safety of a Denver Shunt: A Case Report.","authors":"Keisuke Baba, Tomoki Tanie, Yasuo Matsubara, Yoshihiro Hirata, Hiroaki Ikematsu, Narikazu Boku","doi":"10.1159/000543892","DOIUrl":"https://doi.org/10.1159/000543892","url":null,"abstract":"<p><strong>Introduction: </strong>Malignant ascites due to peritoneal metastasis of gastric cancer is challenging to manage, especially in frail and elderly patients. Traditional treatments like diuretics and paracentesis offer limited relief and can lead to complications such as malnutrition and dehydration. The Denver shunt, a type of peritoneal venous shunt (PVS), can alleviate symptoms but carries risks of severe complications like acute heart failure and disseminated intravascular coagulation (DIC). Assessing patient tolerance before Denver shunt insertion is crucial to prevent life-threatening events.</p><p><strong>Case presentation: </strong>An 82-year-old woman with advanced gastric cancer developed refractory malignant ascites unresponsive to diuretics and cell-free and concentrated ascites reinfusion therapy (CART). Given her age and frailty, along with the small amount of blood in the ascites, there were concerns about the risks associated with a Denver shunt. An extracorporeal PVS was employed to reinfuse ascites at a controlled rate using an infusion pump. The infusion started at 40 mL/h and was carefully monitored. When the patient experienced paroxysmal supraventricular tachycardia at 60 mL/h, the rate was reduced, and β-blocker therapy was initiated. No signs of heart failure, infusion reactions, or DIC were observed during the 8-day extracorporeal reinfusion. After confirming stable laboratory tests including D-dimer levels which elevated slightly on day 3 and decreased on day 7 without intervention, a Denver shunt was safely inserted without severe complications. Thereafter, patient's ascites was effectively managed, not deteriorating her quality of life, until her passing away 2 months later.</p><p><strong>Conclusion: </strong>This case suggests that extracorporeal PVS, in which controlled reinfusion of ascites for several days can prevent acute complication and monitor potential adverse events, can be a valuable prior treatment before Denver shunt insertion in patients with malignant ascites, especially for frail and elderly patients.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"286-295"},"PeriodicalIF":0.7,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11867636/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemorrhagic Shock Caused by an Aggressive Fibromatosis in the Gastropancreatic Region: A Case Report.","authors":"Xiufang Yang, Ziwei Xu","doi":"10.1159/000544814","DOIUrl":"10.1159/000544814","url":null,"abstract":"<p><strong>Introduction: </strong>Aggressive fibromatosis (AF), also known as desmoid tumor, is a rare condition characterized by the proliferation of monoclonal fibroblasts, primarily originating from connective tissue. Despite being histologically benign, AF exhibits malignant-like behavior, including local invasion and a high recurrence rate. AF can be classified based on its location into extra-abdominal, abdominal wall, and intra-abdominal types. Intra-abdominal AF (IAF), though least common, has the worst prognosis and highest mortality rate. Traditionally, complete surgical resection (R0) was the preferred treatment, but recent strategies favor conservative management, especially for asymptomatic patients. Emergency surgery is reserved for complications like bleeding, perforation, or obstruction.</p><p><strong>Case presentation: </strong>This report details a rare case of IAF in the retroperitoneum of a 39-year-old woman presenting with hemorrhagic shock. Emergency surgery, including partial distal pancreatectomy and partial gastrectomy, was performed. The tumor was β-catenin positive, confirming the diagnosis of IAF. Postoperatively, the patient recovered well and showed no recurrence after 2 years without additional therapy.</p><p><strong>Conclusion: </strong>In summary, IAF presents significant diagnostic and therapeutic challenges. Effective management relies on a multidisciplinary approach, combining various diagnostic tools to improve early detection and patient outcomes. Continued research is essential to understand the pathogenesis of AF and to develop less invasive treatment options.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"436-442"},"PeriodicalIF":0.7,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11952818/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrent Spontaneous Tumor Lysis Syndrome in Undiagnosed Follicular T-Cell Lymphoma.","authors":"Feehaan H Sultan, Priya K Jindal, Zeeshaan H Sultan, Nahush R Bansal, Shuhao Qiu","doi":"10.1159/000544865","DOIUrl":"10.1159/000544865","url":null,"abstract":"<p><strong>Introduction: </strong>Spontaneous tumor lysis syndrome (TLS) is a rare, life-threatening metabolic complication that typically occurs in malignancies with high tumor burden. Early recognition is critical, even in the absence of a known malignancy, to prevent severe outcomes.</p><p><strong>Case presentation: </strong>We report the case of an 89-year-old male with a history of chronic kidney disease, hyperparathyroidism, and myasthenia gravis, who experienced three episodes of TLS within 1 month. Initially, his metabolic disturbances were misattributed to dehydration. During his second admission, imaging revealed extensive lymphadenopathy, and a lymph node biopsy confirmed follicular helper T-cell lymphoma before his third hospitalization. Despite aggressive treatment, he developed metabolic encephalopathy and lost his decision-making capacity, while his family declined palliative care discussions.</p><p><strong>Conclusion: </strong>This case highlights the importance of considering TLS in patients with unexplained hyperkalemia, hyperuricemia, and hyperphosphatemia, even in the absence of a malignancy diagnosis. Early diagnosis and multidisciplinary care are essential to improve outcomes.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"413-419"},"PeriodicalIF":0.7,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11949513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144214930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}